FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.

The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide new therapeutic opportunities for treatment of FP-RMS. Herein...

Descripción completa

Detalles Bibliográficos
Autores principales: Milewski, David, Shukla, Samriddhi, Gryder, Berkley E., Pradhan, Arun, Donovan, Johnny, Sudha, Parvathi, Vallabh, Sushmitha, Pyros, Athena, Xu, Yan, Barski, Artem, Szabo, Sara, Turpin, Brian, Pressey, Joseph G., Millay, Douglas P., Khan, Javed, Kalinichenko, Vladimir V., Kalin, Tanya V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005492/
https://www.ncbi.nlm.nih.gov/pubmed/33627785
http://dx.doi.org/10.1038/s41388-021-01694-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005492/
https://www.ncbi.nlm.nih.gov/pubmed/33627785
http://dx.doi.org/10.1038/s41388-021-01694-9

Ejemplares similares